CTLT Catalent Inc

On June 27, 2023 (the “Closing Date”), JP Morgan Chase Bank, N.A, as the administrative agent (in such capacity, the “Administrative Agent”) executed Amendment No. 8 to Amended and Restated Credit Agreement (“Amendment No. 8”), which Amendment No. 8 amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014, among Catalent Pharma Solutions, Inc. (the “Borrower”) and a wholly owned subsidiary of Catalent, Inc. (the “Company”), PTS Intermediate Holdings LLC (“Holdings”), the subsidiaries of the Borrower party thereto, JP Morgan Chase Bank, N.A., as the Administrative Agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto (as amended by Amendment No. 1 dated as of December 1, 2014, Amendment No. 2 dated as of December 9, 2016, Amendment No. 3 dated as of October 18, 2017, Amendment No. 4 dated as of May 17, 2019, Amendment No. 5 dated as of February 22, 2021, Amendment No. 6 dated as of September 29, 2021, Amendment No. 7 dated as of November 22, 2022, and Amendment No. 8, the “Credit Agreement”). Pursuant to Amendment No. 8, effective as of July 1, 2023, the Administrative Agent replaced the London Interbank Offered Rate interest rate benchmark applicable to outstanding term loans with the Secured Overnight Financing Rate (“SOFR”) benchmark. Amendment No. 8 includes a 0.1148% credit spread adjustment to the SOFR benchmark for loans with a 1-month interest period, a 0.26161% credit spread adjustment to the SOFR benchmark for loans with a 3-month interest period and a 0.42826% credit spread adjustment to the SOFR benchmark for loans with a 6-month interest period. Other than the foregoing, the material terms of the Credit Agreement remain unchanged.

The foregoing description of Amendment No. 8 does not purport to be complete and is subject to, and qualified in its entirety by, the full text of Amendment No. 8, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.